Teprotumumab – selektive IGF-1-Rezeptor-Blockade verbessert signifikant die endokrine Orbitopathie beim Morbus Basedow

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Z Gastroenterol 2020; 58(05): 461-462
DOI: 10.1055/a-1129-3532

Kommentiertes Referat

Teprotumumab – selective IGF-1-receptor blockade improves significantly endocrine opthalmopathy in Basedowʼs disease

Stefan Sürig

Medizinische Klinik I, Klinikum Braunschweig

Douglas et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020; 382: 341–352

Article published online:
11 May 2020